CA2391422A1 - Rifampin (rifadin, rimactone, rifampicin) and doxycycline, (doryx, vibramycin) and the tetracyclines and other compounds currently classified as antibiotics and anti-tuberculous drugs as a treatment to prevent, modify disease progression and/or improve symptoms for neurodegenerative diseases including alzheimers disease, lewy body dementia, schizophrenia,... - Google Patents
Rifampin (rifadin, rimactone, rifampicin) and doxycycline, (doryx, vibramycin) and the tetracyclines and other compounds currently classified as antibiotics and anti-tuberculous drugs as a treatment to prevent, modify disease progression and/or improve symptoms for neurodegenerative diseases including alzheimers disease, lewy body dementia, schizophrenia,... Download PDFInfo
- Publication number
- CA2391422A1 CA2391422A1 CA002391422A CA2391422A CA2391422A1 CA 2391422 A1 CA2391422 A1 CA 2391422A1 CA 002391422 A CA002391422 A CA 002391422A CA 2391422 A CA2391422 A CA 2391422A CA 2391422 A1 CA2391422 A1 CA 2391422A1
- Authority
- CA
- Canada
- Prior art keywords
- antibiotics
- treatment
- doryx
- rifampin
- doxycycline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title description 6
- 229940079593 drug Drugs 0.000 title description 5
- 239000003242 anti bacterial agent Substances 0.000 title description 4
- 229940088710 antibiotic agent Drugs 0.000 title description 4
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 title description 4
- 208000024827 Alzheimer disease Diseases 0.000 title description 3
- 229960001225 rifampicin Drugs 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 title description 2
- 229940075059 doryx Drugs 0.000 title description 2
- 229960003722 doxycycline Drugs 0.000 title description 2
- 201000000980 schizophrenia Diseases 0.000 title description 2
- UHHHTIKWXBRCLT-VDBOFHIQSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;ethanol;hydrate;dihydrochloride Chemical compound O.Cl.Cl.CCO.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O UHHHTIKWXBRCLT-VDBOFHIQSA-N 0.000 title 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 title 1
- 206010061818 Disease progression Diseases 0.000 title 1
- 208000009829 Lewy Body Disease Diseases 0.000 title 1
- 201000002832 Lewy body dementia Diseases 0.000 title 1
- 239000004098 Tetracycline Substances 0.000 title 1
- 230000002365 anti-tubercular Effects 0.000 title 1
- 230000005750 disease progression Effects 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 229940063639 rifadin Drugs 0.000 title 1
- -1 rimactone Chemical compound 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
- 235000019364 tetracycline Nutrition 0.000 title 1
- 150000003522 tetracyclines Chemical class 0.000 title 1
- 229940040944 tetracyclines Drugs 0.000 title 1
- 229940063678 vibramycin Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 230000003542 behavioural effect Effects 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- PGLIUCLTXOYQMV-UHFFFAOYSA-N Cetirizine hydrochloride Chemical compound Cl.Cl.C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PGLIUCLTXOYQMV-UHFFFAOYSA-N 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Pa.n;aoa~O iZLS SLS SOB ~i~ SE:9i~v.ZpOZ/LQ/2L~
Applicant: ' I5x_ lJavid William l~rtolloy 42$ 4rlctley tt~a~i_ RR~ 1 Troy Ontario ~;(5ft ~$C1 Patent Airplication fox Rifampin (Rffadin, rims~tu~n~, rit'ampicin) and Do~rycycli~ac, (doryx, vibramycia) and the t~tra~yciixtes $nd other crlmpnunds cBrrently c.las~ifi~
as Aatibietica and anti-tuberculosis drugs as a treatmetat to- prevent, madfty dlscasc ~arvgre5sian and/or imprnve aym:ptams fair Neurodegenex~atiwe di~oascs iaclnaing Aeimers disease, Levy »~tly 11!emenris, schizophrenia, Purkin~ou'wdnd mood ~disard~rs ~dcpressfon) aad bebarioural problems.
This is an application for a patent for the use of F,ifampin andls~x letrHCycIinos ~cluding Doxycycline and other a~~.ti.-tuberculosis drubs its a treatment fox astaod~g~.r~rtivc rliseaaes such aF, Alzheimer's disease, multiply scloraszsParkinson' disease, ~iuntingtoa Cius~, J~tcab Gs~triz~eld etc:. ''these drugs may also be pffcctive i>
the i~atnnent of mood disorders and behavioural problems:
7fita eppiication i~ ~u~ht r~ecause this is a new indication far these compaundslantibiotics: '(3p to how; theses drugs have not been used and/or appx~wed a~ a treatment of neurode~encrativn disease. W~::h~.va evidence fromclinical studies that suggests that these drugs (cuxrenti3~ alassif ad as antibiotics), in particular r~tfampin and the xetracyclines e.g. doxyeycline tie ga effective new trcatrnent for Alzheimer's disease.
They iinnrmred tnerttory; independ~tce in aatiyities of daily living, mood and bebaviou~r problems in Alzheimer's. Their may also be ~tFeective treatment also tot oilier ucumdcgenerative diseases such a" Frontoternp~r~l dementia; Lewy >aody detrrentia, multiple sclcrc~sis, Crettt~eldt-Jak~sb dise~e !(and rclatEd new variant Creutzf~ldt-Jakob c#isease); Parkinson disease; Progreasi~e suprar~uclear palsy, Huntingtozt GllorGa. 'fla:is Patent also includes tl~e ,rse of tetr:cyclines irr particular cloxycycline and rifampxcin and other anitibiotics and anti-tubex-culcus therapy as a new tr~atment for mc~d disorders and behavioural problans.
These-drugs often potential n~w therapeutic options for the possible pctrvention, disease yodification and/or sympt~~makic treatment of the~c diseases, their synnptums and sighs and mood disorders stud beW vioural pxobleliys. Therefore vsrc would like to patern this new appiicati~n for these and other antibiotics t~rrd atstituberculvus:
therapeutics in the reatmont/preventian of neumdegcnerative dlSCases like Al.zheini~r's? strokes;
multiple sclerosis; pai-kinsons,Disease, Huntiugtor~ Chorea and Lewy $ody dementia:;
schi~..ophrenia: ms~~ud disc~rder~ one, behavioural problems .
This is a new indication for #~ese compounds which ate cutzently classified as antil~icitic5 aithaugil it is not clear at thx~ ft~e what mechanism accounts ~trr their effects. They may yet as antibiotics or they may ~xaYe athez~ actinrrs ind~pendenl of anti-baeteaaal actions that accounts far these effects.
Applicant: ' I5x_ lJavid William l~rtolloy 42$ 4rlctley tt~a~i_ RR~ 1 Troy Ontario ~;(5ft ~$C1 Patent Airplication fox Rifampin (Rffadin, rims~tu~n~, rit'ampicin) and Do~rycycli~ac, (doryx, vibramycia) and the t~tra~yciixtes $nd other crlmpnunds cBrrently c.las~ifi~
as Aatibietica and anti-tuberculosis drugs as a treatmetat to- prevent, madfty dlscasc ~arvgre5sian and/or imprnve aym:ptams fair Neurodegenex~atiwe di~oascs iaclnaing Aeimers disease, Levy »~tly 11!emenris, schizophrenia, Purkin~ou'wdnd mood ~disard~rs ~dcpressfon) aad bebarioural problems.
This is an application for a patent for the use of F,ifampin andls~x letrHCycIinos ~cluding Doxycycline and other a~~.ti.-tuberculosis drubs its a treatment fox astaod~g~.r~rtivc rliseaaes such aF, Alzheimer's disease, multiply scloraszsParkinson' disease, ~iuntingtoa Cius~, J~tcab Gs~triz~eld etc:. ''these drugs may also be pffcctive i>
the i~atnnent of mood disorders and behavioural problems:
7fita eppiication i~ ~u~ht r~ecause this is a new indication far these compaundslantibiotics: '(3p to how; theses drugs have not been used and/or appx~wed a~ a treatment of neurode~encrativn disease. W~::h~.va evidence fromclinical studies that suggests that these drugs (cuxrenti3~ alassif ad as antibiotics), in particular r~tfampin and the xetracyclines e.g. doxyeycline tie ga effective new trcatrnent for Alzheimer's disease.
They iinnrmred tnerttory; independ~tce in aatiyities of daily living, mood and bebaviou~r problems in Alzheimer's. Their may also be ~tFeective treatment also tot oilier ucumdcgenerative diseases such a" Frontoternp~r~l dementia; Lewy >aody detrrentia, multiple sclcrc~sis, Crettt~eldt-Jak~sb dise~e !(and rclatEd new variant Creutzf~ldt-Jakob c#isease); Parkinson disease; Progreasi~e suprar~uclear palsy, Huntingtozt GllorGa. 'fla:is Patent also includes tl~e ,rse of tetr:cyclines irr particular cloxycycline and rifampxcin and other anitibiotics and anti-tubex-culcus therapy as a new tr~atment for mc~d disorders and behavioural problans.
These-drugs often potential n~w therapeutic options for the possible pctrvention, disease yodification and/or sympt~~makic treatment of the~c diseases, their synnptums and sighs and mood disorders stud beW vioural pxobleliys. Therefore vsrc would like to patern this new appiicati~n for these and other antibiotics t~rrd atstituberculvus:
therapeutics in the reatmont/preventian of neumdegcnerative dlSCases like Al.zheini~r's? strokes;
multiple sclerosis; pai-kinsons,Disease, Huntiugtor~ Chorea and Lewy $ody dementia:;
schi~..ophrenia: ms~~ud disc~rder~ one, behavioural problems .
This is a new indication for #~ese compounds which ate cutzently classified as antil~icitic5 aithaugil it is not clear at thx~ ft~e what mechanism accounts ~trr their effects. They may yet as antibiotics or they may ~xaYe athez~ actinrrs ind~pendenl of anti-baeteaaal actions that accounts far these effects.
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002391422A CA2391422A1 (en) | 2002-07-12 | 2002-07-12 | Rifampin (rifadin, rimactone, rifampicin) and doxycycline, (doryx, vibramycin) and the tetracyclines and other compounds currently classified as antibiotics and anti-tuberculous drugs as a treatment to prevent, modify disease progression and/or improve symptoms for neurodegenerative diseases including alzheimers disease, lewy body dementia, schizophrenia,... |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002391422A CA2391422A1 (en) | 2002-07-12 | 2002-07-12 | Rifampin (rifadin, rimactone, rifampicin) and doxycycline, (doryx, vibramycin) and the tetracyclines and other compounds currently classified as antibiotics and anti-tuberculous drugs as a treatment to prevent, modify disease progression and/or improve symptoms for neurodegenerative diseases including alzheimers disease, lewy body dementia, schizophrenia,... |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2391422A1 true CA2391422A1 (en) | 2004-01-12 |
Family
ID=30774464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002391422A Abandoned CA2391422A1 (en) | 2002-07-12 | 2002-07-12 | Rifampin (rifadin, rimactone, rifampicin) and doxycycline, (doryx, vibramycin) and the tetracyclines and other compounds currently classified as antibiotics and anti-tuberculous drugs as a treatment to prevent, modify disease progression and/or improve symptoms for neurodegenerative diseases including alzheimers disease, lewy body dementia, schizophrenia,... |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2391422A1 (en) |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869571A (en) * | 2010-07-14 | 2010-10-27 | 施瑞客（天津）生物技术有限公司 | Doxycycline hydrochloride and rifampicin effervescent granules for livestock and poultry and preparation method thereof |
| WO2014176632A1 (en) * | 2013-04-30 | 2014-11-06 | Borody Thomas J | Compositions and methods for treating microbiota-related psychotropic conditions and diseases |
| US9320763B2 (en) | 2000-07-25 | 2016-04-26 | Thomas Julius Borody | Probiotic recolonisation therapy |
| US9649343B2 (en) | 2011-03-09 | 2017-05-16 | National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) | Compositions and methods for transplantation of colon microbiota |
| US9901603B2 (en) | 2015-05-14 | 2018-02-27 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them |
| US9962413B2 (en) | 2010-08-04 | 2018-05-08 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US10195235B2 (en) | 2016-08-03 | 2019-02-05 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| EP3760204A1 (en) * | 2019-07-03 | 2021-01-06 | Medizinische Universität Graz | Medicament for prevention or treatment of huntington's disease |
| US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| US11202808B2 (en) | 2015-05-22 | 2021-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
| US11357801B2 (en) | 2016-06-15 | 2022-06-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US11433102B2 (en) | 2017-04-05 | 2022-09-06 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Parkinson's disease (PD) and related disorders |
| US11542560B2 (en) | 2012-05-25 | 2023-01-03 | Board of Regents on Behalf of Arizona State University | Microbiome markers and therapies for autism spectrum disorders |
| US11819523B2 (en) | 2016-07-01 | 2023-11-21 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| US11865145B2 (en) | 2017-08-07 | 2024-01-09 | Finch Therapeutics Holdings Llc | Compositions and methods for maintaining and restoring a healthy gut barrier |
| US11890306B2 (en) | 2017-05-26 | 2024-02-06 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
| US11911419B2 (en) | 2018-09-27 | 2024-02-27 | Finch Therapeutics Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
| US12290538B2 (en) | 2019-07-19 | 2025-05-06 | Finch Therapeutics Holdings Llc | Methods and products for treatment of gastrointestinal disorders |
-
2002
- 2002-07-12 CA CA002391422A patent/CA2391422A1/en not_active Abandoned
Cited By (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9623056B2 (en) | 2000-07-20 | 2017-04-18 | Crestovo Llc | Probiotic recolonisation therapy |
| US9468658B2 (en) | 2000-07-25 | 2016-10-18 | Crestovo Llc | Probiotic recolonisation therapy |
| US9737574B2 (en) | 2000-07-25 | 2017-08-22 | Crestovo Llc | Probiotic recolonisation therapy |
| US9408872B2 (en) | 2000-07-25 | 2016-08-09 | Crestovo Llc | Probiotic recolonisation therapy |
| US9962414B2 (en) | 2000-07-25 | 2018-05-08 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
| US9572841B2 (en) | 2000-07-25 | 2017-02-21 | Crestovo Llc | Probiotic recolonisation therapy |
| US9572842B2 (en) | 2000-07-25 | 2017-02-21 | Crestovo Llc | Probiotic recolonisation therapy |
| US9320763B2 (en) | 2000-07-25 | 2016-04-26 | Thomas Julius Borody | Probiotic recolonisation therapy |
| US10772919B2 (en) | 2000-07-25 | 2020-09-15 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
| US9610308B2 (en) | 2000-07-25 | 2017-04-04 | Crestovo Llc | Probiotic recolonisation therapy |
| US9682108B2 (en) | 2000-07-25 | 2017-06-20 | Crestovo Llc | Probiotic recolonisation therapy |
| US9901604B2 (en) | 2000-07-25 | 2018-02-27 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
| US9789140B2 (en) | 2000-07-25 | 2017-10-17 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
| US9867858B2 (en) | 2000-07-25 | 2018-01-16 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
| US10369175B2 (en) | 2000-07-25 | 2019-08-06 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
| CN101869571A (en) * | 2010-07-14 | 2010-10-27 | 施瑞客（天津）生物技术有限公司 | Doxycycline hydrochloride and rifampicin effervescent granules for livestock and poultry and preparation method thereof |
| US11504403B2 (en) | 2010-08-04 | 2022-11-22 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10849937B2 (en) | 2010-08-04 | 2020-12-01 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11103541B2 (en) | 2010-08-04 | 2021-08-31 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10022406B2 (en) | 2010-08-04 | 2018-07-17 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11173183B2 (en) | 2010-08-04 | 2021-11-16 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10064899B1 (en) | 2010-08-04 | 2018-09-04 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11065284B2 (en) | 2010-08-04 | 2021-07-20 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11890307B2 (en) | 2010-08-04 | 2024-02-06 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11207356B2 (en) | 2010-08-04 | 2021-12-28 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10278997B2 (en) | 2010-08-04 | 2019-05-07 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11491193B2 (en) | 2010-08-04 | 2022-11-08 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10987385B2 (en) | 2010-08-04 | 2021-04-27 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10328107B2 (en) | 2010-08-04 | 2019-06-25 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11890308B2 (en) | 2010-08-04 | 2024-02-06 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10463702B2 (en) | 2010-08-04 | 2019-11-05 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11850269B2 (en) | 2010-08-04 | 2023-12-26 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US9962413B2 (en) | 2010-08-04 | 2018-05-08 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10610551B2 (en) | 2010-08-04 | 2020-04-07 | Crestovo Holdings, Inc. | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10617724B2 (en) | 2010-08-04 | 2020-04-14 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10675309B2 (en) | 2010-08-04 | 2020-06-09 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10857188B2 (en) | 2010-08-04 | 2020-12-08 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11541080B2 (en) | 2010-08-04 | 2023-01-03 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11129859B2 (en) | 2010-08-04 | 2021-09-28 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US9649343B2 (en) | 2011-03-09 | 2017-05-16 | National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) | Compositions and methods for transplantation of colon microbiota |
| US11801269B2 (en) | 2011-03-09 | 2023-10-31 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US10286011B2 (en) | 2011-03-09 | 2019-05-14 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US10286012B2 (en) | 2011-03-09 | 2019-05-14 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US10251914B2 (en) | 2011-03-09 | 2019-04-09 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US12295974B2 (en) | 2011-03-09 | 2025-05-13 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US10028980B2 (en) | 2011-03-09 | 2018-07-24 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US9968638B2 (en) | 2011-03-09 | 2018-05-15 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US11542560B2 (en) | 2012-05-25 | 2023-01-03 | Board of Regents on Behalf of Arizona State University | Microbiome markers and therapies for autism spectrum disorders |
| US12084727B2 (en) | 2012-05-25 | 2024-09-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Microbiome markers and therapies for autism spectrum disorders |
| WO2014176632A1 (en) * | 2013-04-30 | 2014-11-06 | Borody Thomas J | Compositions and methods for treating microbiota-related psychotropic conditions and diseases |
| AU2014262125B2 (en) * | 2013-04-30 | 2020-02-13 | Thomas Julius Borody | Compositions and methods for treating microbiota-related psychotropic conditions and diseases |
| US12161678B2 (en) | 2015-05-14 | 2024-12-10 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them |
| US9901603B2 (en) | 2015-05-14 | 2018-02-27 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them |
| US11123377B2 (en) | 2015-05-14 | 2021-09-21 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them |
| US10821138B2 (en) | 2015-05-14 | 2020-11-03 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them |
| US11202808B2 (en) | 2015-05-22 | 2021-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US11357801B2 (en) | 2016-06-15 | 2022-06-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US11819523B2 (en) | 2016-07-01 | 2023-11-21 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| US12186349B2 (en) | 2016-07-01 | 2025-01-07 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| US10195235B2 (en) | 2016-08-03 | 2019-02-05 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| US12390496B2 (en) | 2016-08-03 | 2025-08-19 | Finch Therapeutics Holdings Llc | Methods for treating ulcerative colitis |
| US10561690B2 (en) | 2016-08-03 | 2020-02-18 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| US11071759B2 (en) | 2016-08-03 | 2021-07-27 | Finch Therapeutics Holdings Llc | Methods for treating ulcerative colitis |
| US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
| US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| US11529375B2 (en) | 2017-04-05 | 2022-12-20 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| US11433102B2 (en) | 2017-04-05 | 2022-09-06 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Parkinson's disease (PD) and related disorders |
| US11890306B2 (en) | 2017-05-26 | 2024-02-06 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
| US11865145B2 (en) | 2017-08-07 | 2024-01-09 | Finch Therapeutics Holdings Llc | Compositions and methods for maintaining and restoring a healthy gut barrier |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| US12285447B2 (en) | 2018-07-13 | 2025-04-29 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| US11911419B2 (en) | 2018-09-27 | 2024-02-27 | Finch Therapeutics Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
| EP3760204A1 (en) * | 2019-07-03 | 2021-01-06 | Medizinische Universität Graz | Medicament for prevention or treatment of huntington's disease |
| US12290538B2 (en) | 2019-07-19 | 2025-05-06 | Finch Therapeutics Holdings Llc | Methods and products for treatment of gastrointestinal disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2391422A1 (en) | Rifampin (rifadin, rimactone, rifampicin) and doxycycline, (doryx, vibramycin) and the tetracyclines and other compounds currently classified as antibiotics and anti-tuberculous drugs as a treatment to prevent, modify disease progression and/or improve symptoms for neurodegenerative diseases including alzheimers disease, lewy body dementia, schizophrenia,... | |
| WO2020132066A8 (en) | Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof | |
| MXPA04005376A (en) | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses. | |
| GEP20033067B (en) | C-21 Modified Epothilones | |
| WO2004009062A3 (en) | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau | |
| WO2001074898A3 (en) | Charged compounds comprising a nucleic acid binding moiety and uses therefor | |
| NO20053855L (en) | 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases. | |
| CA2514473A1 (en) | Fused bicyclic nitrogen-containing heterocycles | |
| WO1996037605A3 (en) | Anti sense oligonucleotides for blocking ige receptor synthesis | |
| TR200201094T2 (en) | Bicyclic amino acids as pharmaceuticals | |
| CA2368843A1 (en) | Neurotrophic substituted pyrimidines | |
| WO2007092329A3 (en) | Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders | |
| BR0114344A (en) | Retinoids for Emphysema Treatment | |
| EP3982819A4 (en) | Methods for evaluation and treatment of alzheimer's disease and applications thereof | |
| Gibson | Human health: the contribution of microorganisms | |
| IL163951A (en) | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | |
| Sowmiya et al. | Adsorption of RGD tripeptide on anatase (0 0 1) surface–A first principle study | |
| EP1564291A3 (en) | Oligonucleotides, agents containing them and their use | |
| WO2006067414A3 (en) | Glycine transport inhibitors | |
| ZA200700945B (en) | Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases | |
| IL172229A (en) | Use of pyrazolopyridines for the preparation of pharmaceutical compositions for improving perceptive cognition | |
| WO2005012490A3 (en) | Neuroprotective effects of atf6 | |
| WO2005109313A3 (en) | Enclosing drugs with synthetic oligonucleotides | |
| WO2004038422A3 (en) | Inhibitors of src kinase for use in alzheimer's disease | |
| HK40074615A (en) | Methods for evaluation and treatment of alzheimer's disease and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |